Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
Rhea-AI Summary
Oncocyte Corp (NASDAQ: OCX), a diagnostics technology company, announced its participation in the 17th annual LD Micro Main Event in Los Angeles. CEO Josh Riggs is scheduled to present on Tuesday, October 29th at 2:30 PM PT at The Luxe Sunset Boulevard Hotel. The company's management will also be available for one-on-one meetings with investors.
The LD Micro Main Event XVII will run from October 28th to 30th, featuring approximately 150 companies presenting in half-hour increments and attending private meetings with investors. Registration begins on October 28th at 3:00 PM PT, followed by keynotes and a happy hour. Presentations will run from 8:00 AM to 5:00 PM PT on October 29th and 30th.
Positive
- None.
Negative
- None.
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro Conference platform.
Event: LD Micro Main Event XVII
Date: Tuesday, October 29th
Presentation Time: 2:30 PM PT
Location: The Luxe Sunset Boulevard Hotel, Los Angeles
To register to watch the virtual presentation, please click here.
Summary of LD Micro Main Event XVII
The 2024 LD Micro Main Event XVII will run from October 28th to the 30th at the Luxe Sunset Boulevard Hotel in Los Angeles. Registration begins at 3:00 PM PT on October 28th followed by keynotes and happy hour. Presentations will run from 8:00 AM PT to 5:00 PM PT on October 29th and 30th. This three-day event will feature around 150 companies, presenting in half-hour increments, and attending private meetings with investors.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through the LD Micro Index and annual investor conferences, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When and where is Oncocyte (OCX) presenting at the LD Micro Main Event XVII?
Who will be presenting for Oncocyte (OCX) at the LD Micro Main Event XVII?
How can investors schedule one-on-one meetings with Oncocyte (OCX) management?
What are the dates for the LD Micro Main Event XVII where Oncocyte (OCX) is participating?
